Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › IL-2

IL-2

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of IL-2

13 trials tracked of IL-2: 1 in phase 3 or 4.

13Trials tracked
1Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 1 Phase 2 10 Phase 1 2
  1. Phase 4 Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment Completed
  2. Phase 2 In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis Completed
  3. Phase 2 Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer Completed
  4. Phase 2 Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC) Completed
  5. Phase 2 Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer Completed
  6. Phase 2 High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer Completed
Show 7 more trials
  1. Phase 2 Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma Completed
  2. Phase 2 Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People Completed
  3. Phase 2 Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD Completed
  4. Phase 2 Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma Completed
  5. Phase 2 Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma Completed
  6. Phase 1 FT516 and IL2 With Enoblituzumab for Ovarian Cancer Completed
  7. Phase 1 Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC Completed

Showing the 13 most-cited and recently-updated of 13 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Review synthesizes Treg biology and NB-UVB, JAK inhibitors, IL-2 in vitiligo patients
Allergy & Immunology Sys. Review
Review synthesizes Treg biology and NB-UVB, JAK inhibitors, IL-2 in vitiligo patients Review shows immune cells may be off in vitiligo
This narrative review examines Treg biology and immunoregulatory functions alongside NB-UVB, JAK inhibitors, and low-dose IL-2 in vitiligo p…
A review finds immune cells that calm inflammation are fewer and less effective in people with vitiligo, suggesting a path for future treatm…
Frontiers May 18, 2026
Network meta-analysis compares biologics and targeted drugs for systemic lupus erythematosus efficacy and safety
Infectious Disease Meta-analysis
Network meta-analysis compares biologics and targeted drugs for systemic lupus erythematosus efficacy and safety New Lupus Treatments Show Stronger Results With Fewer Side Effects
This systematic review and network meta-analysis of 17,121 patients with systemic lupus erythematosus compared biologics and targeted small …
Certain new lupus drugs help more people feel better with fewer flare-ups, especially those struggling with rashes or joint pain that older …
Frontiers May 2, 2026
Systematic review examines IL-15-based immunotherapy for cancer with manageable toxicity profiles
Allergy & Immunology Sys. Review
Systematic review examines IL-15-based immunotherapy for cancer with manageable toxicity profiles New Immune Booster Could Help Cancer Fighters Last Longer
A systematic review evaluated IL-15-based cancer immunotherapy, including recombinant IL-15 and immunocytokines, for cancer treatment.
A new immune booster helps cancer fighters stay active longer, potentially making treatments for solid tumors and CAR-T therapy work far bet…
Frontiers Apr 16, 2026